As of early 2012, clinical trials of IL - 17
antibodies against psoriasis have shown promising results in Phase II.
Not exact matches
In a previous study published in 2012, researchers treated
psoriasis patients with
antibodies that attack IL - 17A and with a substance, called an antagonist, that acts
against tumour necrosis factor, another cytokine strongly implicated in
psoriasis.
Key Highlight: • Facilitated the introduction of HUMIRA (adalimumab) for the healthcare professionals as the latest and the only fully human monoclonal
antibody against TNF for the treatment of moderate to severe
psoriasis in patient failed at least on two DMARD's.